Antioxidant Support to Lead Functionality Segment with 37.2% Market Share in 2025 Antioxidant support is expected to remain the most lucrative segment, holding a market share of approximately 37.2% in 2025
However, contrary to the tumor-promoting potential of many angiogenic agents, BPC-157 has been shown to inhibit uncontrolled cell proliferation, downregulate VEGF expression, and counteract VEGF-driven tumorigenesis, including suppression of Ki-67 and VEGF pathway activation [31, 73]
empty gelatin capsule (EGC), size 00 with white body and white cap, printed with Snow Caps Product Warning: No approved therapeutic claims
It is presented here for research and educational purposes only
If you notice any unusual symptoms or have concerns during your treatment, dont hesitate to reach out to your healthcare provider
Any concerns or questions are addressed before treatment begins